Abstract：【Objective】To investigate the efficacy and safety of sequential calcium dialysis in patients with maintenance hemodialysis (HD) complicated with hypertension. 【Methods】Changes of blood pressure, serum calcium, blood phosphorus, parathyroid hormone (PTH) levels before and after sequential calcium dialysis treatment in 25 patients with maintenance HD with hypertension were compared. 【Results】Sequential calcium dialysis effectively reduced systolic blood pressure, diastolic blood pressure and mean arterial blood pressure during hemodialysis. The overall effective rate was 89.5% (17/25). The effective rate of hypotension was 73.3% (11/15) in male patients and 100% (10/10) in female patients; The difference was significant (P<0.05). The antihypertensive effective rate of patients under 60 years old was lower than that of patients over 60 years old, and the difference was significant (P<0.05). In patients with dialysis maintenance time of 1-3 years, the effective antihypertensive rate was 62.5% (5/8). The effective hypotensive rate of patients with 3-7 years maintenance was 91.67% (11/12 patients). The effective rate of hypotension was 100% (5/5) in patients with 8-9 years of maintenance dialysis. The longer the dialysis time was, the higher the effective hypotension rate was, and there was significant difference in between the two variables (P<0.05). There was no significant difference in serum calcium concentration and PTH level before and after sequential calcium dialysis treatment (P>0.05). 【Conclusion】 Sequential calcium dialysis can effectively reduce blood pressure during dialysis, and has a significant effect on female patients and elderly patients with longer dialysis maintenance time. It has no significant effect on serum calcium concentration and PTH level, which is safe in clinical application.
[1] 戴兵,梅长林.透析高血压的发病机制及治疗进展[J].中国血液净化, 2007,6(1):5. [2] INRIG J K.Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients[J].Kidney Int,2007,71(5):454-461. [3] 孟建中,周春华,刘子栋,等.血液净化技术并发症诊断与治疗[M]. 天津:天津科学技术出版社, 2015:78. [4] 中华医学会老年医学分会肾病学组, 国家老年疾病临床医学研究中心. 老年慢性肾脏病诊治的中国专家共识(2018)[J].中华老年医学杂志, 2018, 37(7):725-731. [5] TONG A, CHANDO S, CROWE S, et al. Research priority setting in kidney disease: a systematic review[J].Am J Kidney Dis,2015, 65(5):674-683. [6] 郭玉,张青.1.5 mmol/L钙浓度透析液对钙磷代谢及血清全段甲状旁腺激素的长期影响[J].中国血液净化, 2006,11(5):203-204. [7] MA H, SANDOR D G, BECK L J. The role of complement in membranous nephropathy[J].Semin Nephrol,2013,33(6):531-542. [8] 张灵灵. 血液透析联合血液灌流治疗老年血液透析合并慢性肾脏病矿物质和骨代谢异常的效果及对BMP、iPTH、甲状腺素水平的影响[J].中国老年学杂志, 2018,38(9):125-127. [9] SALANT D J. Unmet challenges in membranous nephropathy[J].Curr Opin Nephrol Hypertens,2019,28(1):70-76. [10] 雷磊. 高通量血液透析联合血液灌流对终末期肾病患者中大分子溶质清除效果的影响[J].医药论坛杂志, 2018, 39(2):99-101. [11] PORT F K,ROBINSON B M,MCCULLOUGH K P,et al.Predialysis blood pressure on survival in hemodialysis patients[J].Kidney Int,2017,91(3):755-756.
2021, Vol. 38 
